Calprotectin and periostin levels in periodontitis patients with coronary artery disease

Abstract

ObjectiveThe aim of the study was to assess the effect of non‐surgical periodontal therapy (NSPT) on periodontal and cardiac parameters as well as on the expression of calprotectin and periostin levels in periodontitis patients with and without coronary artery disease (CAD).MethodsNinety subjects were categorised into three groups: Group H: periodontally and systemically healthy subjects, Group P: stage III grade B periodontitis subjects with no associated systemic diseases and Group P + CAD: stage III grade B periodontitis subjects diagnosed with CAD. Demographic, periodontal and cardiac parameters were recorded at baseline (0 day) and on the 180th day after NSPT. Gingival crevicular fluid was collected from all participants at baseline (0 day) and after the 180th day. Calprotectin and periostin expression were reassessed.ResultsA significant increase in the levels of calprotectin (34.05 ± 11.72) was seen at baseline in the P + CAD group, whereas on the contrary, a decreased periostin (1.59 ± 0.41) was also noted at baseline. The study also showed a significant improvement in periodontal and cardiac parameters on the 180th day following NSPT.ConclusionDetection of calprotectin and periostin expression in GCF samples could represent a link to the association of periodontitis and CAD.

Systemic Impact of Subgingival Infection Control in Periodontitis Patients with Cardiovascular Disease: A Narrative Review

“…Elevated release of S100A8/A9 appears to exert deleterious effects during myocardial infarction and is linked to an unfavorable long-term prognosis [84], while the inhibition of S100A8/A9 has been effective in myocardial infarction models [80]. The reduction of serum S100A8/A9 through nonsurgical periodontal therapy [63] seems an appealing perspective in CVD individuals. However, more clinical trials should further establish the impact of periodontitis infection control on S100A8/A9 concentrations in this group of patients.…”

“…Limited data are available regarding changes in serum calprotectin (S100A8/A9) levels among patients with periodontitis and CVD. A single study reported a notable rise in calprotectin levels in individuals with both periodontitis and coronary artery disease, which subsequently decreased 180 days after nonsurgical periodontal treatment alongside improvements in cardiac parameters [63].…”